Long-term combination therapy with ezetimibe and acarbose improved insulin sensitivity in a high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) mouse model by upregulating the mRNA expression of peroxisome proliferators-activated receptor-alpha (PPAR-α) 1 and microsomal triglyceride transfer protein (MTP) in hepatocytes (110). Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.